CLEVELAND, Oct. 7, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that patient treatments are
scheduled to begin in Boston with
ViewRay's MRIdian® Linac System at Dana-Farber/Brigham and Women's
Cancer Center. The MRIdian provides for the delivery of radiation
therapy to targeted tumors while simultaneously providing
continuous magnetic resonance imaging (MRI).
"We will now be able to adapt the therapy to changes in the
patient's body such as movement caused by breathing or digestion,
to target cancer more accurately and deliver radiation only when
the tumor is in the proper position," said Daphne Haas-Kogan, M.D., chair Department of
Radiation Oncology, Dana-Farber/Brigham and Women's Cancer
Center.
The new MRI-guided radiation therapy will be used to treat many
different cancer types. Its greatest potential advantage will be in
treating soft-tissue tumors – including breast, gastrointestinal,
gynecological, prostate, pancreas, sarcoma, and head and neck
tumors – and for tumors that are highly mobile, such as lung
cancers.
"This new technology offers substantial clinical benefit by
providing greater resolution of soft tissue tumors, allowing for
more precise tumor targeting and less radiation exposure thus
sparing healthy tissue," said Raymond
Mak, M.D., lead radiation oncologist for MRI-Guided
Radiation Therapy at Dana-Farber/Brigham and Women's Cancer Center.
"This cutting-edge technology allows us to personalize and adapt
each treatment in ways we never could before."
"Dana Farber/Brigham and Women's
is a world leader in adult and pediatric cancer treatment and
research," said Scott Drake,
President and CEO of ViewRay. "We share a common mission to
eradicate cancer with the use of innovative technologies, and we
look forward to further serving patients."
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that potentially may arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2019 and ViewRay's conference call to discuss its second
quarter results. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to commercialize MRIdian
Linac System, demand for ViewRay's products, the ability to convert
backlog into revenue, and the timing of delivery of ViewRay's
products, the timing, results and other uncertainties associated
with clinical trials, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to ViewRay's
business in general, see ViewRay's current and future reports filed
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Reports on
Form 10-Q for the fiscal quarters ended March 31, 2019 and June
30, 2019, as updated periodically by the company's other
filings with the SEC. These forward-looking statements are made as
of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/patient-treatments-with-viewrays-mridian-linac-begin-in-new-england-300931538.html
SOURCE ViewRay, Inc.